A critical advance in cancer research is emerging with the use of nanobodies to re-engage mutated p53. This vital tumor inhibitor protein is frequently inactivated in several kinds of malignancies, resulting https://johsocial.com/story12670959/mini-antibodies-reactivate-tumor-suppressor-p53-the-new-hope-for-malignant-therapy